Generics Call Alcon Glaucoma Drug Obvious As Trial Begins
Two generic-drug makers seeking to invalidate a glaucoma treatment patent owned by a Novartis AG spinoff started off a London trial Tuesday by saying the treatment would be obvious to anyone...To view the full article, register now.
Already a subscriber? Click here to view full article